In an online interview, published yesterday by leading oncology channel ecancer, Joaquin Mateo, Principal Investigator of VHIO’s Prostate Cancer Translational Research Group, discusses just some of the multi-center studies in which he has participated that seek to develop more potent and personalized PARP inhibitors for the targeted treatment of patients suffering from advanced prostate cancer.
More specifically, he highlights the international PROfound trial; results from which were recently published in The New England Journal Medicine*, which Joaquin co-authored. This study is not only opening up much needed and new treatment avenues with PARPi for patients with metastatic castration-resistant prostate cancer, but is also illustrative of just how researchers are rapidly ringing in a new era of precision medicine to more effectively combat this disease.
Joaquin, who is also a Medical Oncologist of VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group, directed by Joan Carles, the Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, then goes on to talk about the importance of incorporating genomics for the optimal stratification of these patients, as well as the promise of ongoing and future trials combining PARPi with other treatments to reverse resistance to these targeted therapies.
To discover more, please access ecancer’s interview here:
*Johann de Bono, Joaquin Mateo , Karim Fizazi , Fred Saad , Neal Shore , Shahneen Sandhu , Kim N Chi , Oliver Sartor , Neeraj Agarwal , David Olmos , Antoine Thiery-Vuillemin, Przemyslaw Twardowski , Niven Mehra , Carsten Goessl , Jinyu Kang , Joseph Burgents , Wenting Wu , Alexander Kohlmann, Carrie A Adelman, Maha Hussain. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102.doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.